Skip to content
Search

Latest Stories

Boots closing two stores in North Wales in early 2024

Boots closing two stores in North Wales in early 2024

A petition has been launched to save a Boots pharmacy in Bournville from closure

The pharmacy chain has already announced plans to permanently close hundreds of its branches across the UK to consolidate its portfolio of 2,200 stores to 1,900.


Two of its branches in North Wales will be closed next year, with its site in Rhos on Sea set to close its doors in March 2024 and the shop in Colywn Bay the following month.

In a statement obtained by The Sun, Clwyd West MP David Jones has branded the closures "hugely bad news for the local community".

He added that it is not “a case of simple shop closures,” but “another body blow for the local retail economy.”

The Station Road shopping centre, where the Colwyn Bay store is located, has already seen the closure of several other prominent stores, including WHSmith, the MP stated.

The closure of two Boots stores will leave many people “extremely worried as to how they will be able to obtain essential medicines,” he added.

Meanwhile, a petition has been launched to save the St Andrews Parade pharmacy in Bournville from closure.

Cllr Catherine Gibbons have also joined residents to convince the company to backtrack on its decision.

The petition obtained by Weston Mercury reads: "Our town is home to a significant number of elderly and disabled individuals who require regular medication. The closure of this pharmacy would mean that they would have to travel further distances to access their prescriptions, which would be detrimental to their health and further worsen health inequalities for the most in need.

"We know pharmacies play a crucial role in providing quality healthcare services across the UK.

"The closure of our local Boots pharmacy would not only disrupt these essential services but also put additional pressure on other healthcare providers in our community."

Boots has already closed a number of its branches in Flintshire, Wales, Leicester, York, Plymouth and Exeter, and is s pulling down the shutters on its site in Wigan and Norwich in early 2024.

More For You

Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less
Three pharmacists named in NIHR’s latest cohort of senior investigators

L-R: Professor David Alldred; Professor Rachel Elliott and Professor Ian Maidment.

Three pharmacists appointed as NIHR senior investigators

The National Institute for Health and Care Research (NIHR) has announced its latest cohort of senior investigators, including three distinguished pharmacists.

David Alldred, professor of medicines use and safety at the University of Leeds; Rachel Elliott, professor of health economics at the University of Manchester; and Ian Maidment, professor in clinical pharmacy at Aston University, have been named in the list of 39 new appointments, alongside 19 reappointed senior investigators.

Keep ReadingShow less
Vaccine-preventable infections costing UK billions

Effective interventions are needed to prevent hospitalisations

Vaccine-preventable infections costing UK billions

Effective interventions are having a positive impact but more needs to be done to combat vaccine-preventable infections after data revealed today showed that it accounted for 20 per cent of hospital bed usage in the UK between 2023 to 2024 at a cost of almost £6 billion.

The return of social mixing, international travel and migration following the COVID-19 pandemic have contributed to the rise in both endemic disease and vaccine-preventable infections, according to the UK Health Security Agency's (UKHSA).

Keep ReadingShow less